MYDA Advisors’s CRISPR Therapeutics CRSP Stock Holding History

MYDA Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,000	Closed	-$853K	–	130
2019 Q4	$853K	Buy	+14,000	New	+$764K	0.37%	62

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MYDA Advisors's CRSP Position: Q1 2020 in Review

MYDA Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 14,000 shares — an estimated $853K sold.

MYDA Advisors first reported a position in CRSP in Q4 2019 and held it in 1 quarter. The position peaked at $853K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

MYDA Advisors reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
MYDA Advisors sold 14,000 CRISPR Therapeutics shares in Q1 2020, an estimated $853K.
MYDA Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 1 quarter.
MYDA Advisors's CRISPR Therapeutics position peaked at $853K in Q4 2019.
257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.